ClinicalTrials.gg
RecruitingNCT05931276BRAVOUpdated Oct 13, 2026

CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

A Phase 3 interventional study of Metoprolol Succinate and Carvedilol in End-Stage Kidney Disease and End-Stage Renal Disease, sponsored by VA Office of Research and Development. Recruiting at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by VA Office of Research and Development · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.
Updated Oct 13, 2026Site recruiting status changed10 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,540
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Planned enrollment
16th of 638
2,540 · median 48
Started
2024
with 23 others
Phase 3
76 of 765
4 open now
Primary completion
2026-12
later than 19 of 95 live
Registered
658th of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 16th largest by planned enrollment of the 638 interventional ones that give a count, is one of 24 that started in 2024, is one of 76 in phase 3, reaches primary completion later than 19 of the 95 other live ones, and was the 658th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.

Read the detailed description

Approximately 35,000 Veterans have end stage kidney disease (ESKD) with an incidence of 13,000 annually. These numbers are increasing because of the epidemic of diabetes, the most common cause of ESKD, among the Veteran population. Patients with ESKD on hemodialysis have substantial cardiovascular morbidity. Veterans annual mortality is in excess of 15% and more than half the deaths are due to cardiovascular disease. Beta blockers have been shown to prevent cardiovascular events in randomized clinical trials in patients without chronic kidney disease, particularly those with heart failure and after myocardial infarction. Beta blockers are a mainstay of therapy in dialysis patients, with two-thirds of Veterans on dialysis receiving a beta blocker. There are no head-to-head randomized studies comparing the two most commonly used beta blockers in ESKD patients in the United States, metoprolol and carvedilol, but observational studies suggest superior outcomes for patients treated with metoprolol. The identification of the superior beta blocker may significantly improve the morbidity and mortality of the VA dialysis population.

The investigators aim to compare two beta blockers with similar indications, usage and availability within the VA but with major differences in patients dialysis clearance and adrenergic effects. The investigators aim to determine if patients undergoing dialysis have improved survival when using metoprolol succinate, a beta blocker that is removed by dialysis and is beta-1 selective, compared to carvedilol, a beta blocker that is not removed by dialysis and is not beta-selective and is also an alpha-blocker.

03

Conditions studied

  • End-Stage Kidney Disease
  • End-Stage Renal Disease

Keywords

  • Dialysis
  • beta-Blockers, Adrenergic
  • Cardiovascular Diseases
  • Point of Care Research
  • Comparative Effectiveness Research
  • Metoprolol Succinate
  • Carvedilol
  • Hemodialysis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • On hemodialysis
  • Received one of the following beta blockers through the VA pharmacy: metoprolol (succinate or tartrate), atenolol, labetalol, carvedilol, bisoprolol

Exclusion criteria

Exclusion Criteria:

  • Impaired decision-making capacity
  • Patients not receiving carvedilol who have a history of asthma
  • known to any component of either drug
  • Provider unwilling to sign a new medication order for a randomized patient
  • No surrogate consent will be allowed
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,540 participants (estimated)

Study arms

  • Active comparator
    Metoprolol Succinate

    Depending on baseline type and dose of beta blocker: * 25 milligrams once daily (12.5 milligrams once daily if \> NYHA class II) * 50 milligrams (or 25 milligrams) once daily * 100 milligrams (or 50 milligrams) once daily * 200 milligrams (or 100 milligrams titrated to 200 milligrams) once daily

    Drug: Metoprolol Succinate

  • Active comparator
    Carvedilol

    Depending on baseline type and dose of beta blocker: * 3.125 milligrams twice daily * 6.25 milligrams twice daily * 12.5 milligrams twice daily * 25 milligrams twice daily (may titrate to 5 0 milligrams twice daily if \> 85 kilograms)

    Drug: Carvedilol

Interventions

06

What researchers measure

Primary outcomes

  1. Time to major cardiovascular event

    The Primary outcome measure will be time to a non-fatal adverse cardiovascular event, defined as a composite outcome comprised of the first occurrence after randomization of any of the following: myocardial infarction, stroke, or hospitalization for heart failure, and all-cause mortality

    Time frame: Randomization to time to event; average follow-up 3 years

Secondary outcomes

  1. Non-fatal myocardial infarction

    Non-fatal myocardial infarction

    Time frame: Randomization to time to event; average follow-up 3 years

  2. Non-fatal stroke

    Non-fatal stroke

    Time frame: Randomization to time to event; average follow-up 3 years

  3. Hospitalization for heart failure

    Hospitalization for heart failure

    Time frame: Randomization to time to event; average follow-up 3 years

  4. All-cause mortality

    All-cause mortality

    Time frame: Randomization to time to event; average follow-up 3 years

Other outcomes

  1. All-cause hospitalization

    All-cause hospitalization

    Time frame: Randomization to time to event; average follow-up 3 years

  2. ED visit or hospitalization possibly related to low BP including falls, fractures, hypotension, or serious injury

    Number of emergency department visits or hospitalization for events that may be a consequence of low blood pressure or beta blocker excess or withdrawal including falls, fractures, hypotension, or serious injury

    Time frame: Number of events; average follow-up 3 years

  3. Use of BP raising medications

    Use and dose of midodrine

    Time frame: Use of drug; average follow-up 3 years

  4. ED or hospital visits for atrial fibrillation and uncontrolled rate

    Emergency department visit or hospitalization for atrial fibrillation with uncontrolled rate (to capture poor control with beta blocker withdrawal)

    Time frame: Randomization to time to event; average follow-up 3 yars

07

Study locations

12 of 18 sites recruiting
08

References and documents

Publications

  • Leatherman SM, Ishani A. Point-of-Care Clinical Trials in Nephrology. J Am Soc Nephrol. 2024 Jun 1;35(6):812-814. doi: 10.1681/ASN.0000000000000340. Epub 2024 Feb 29. No abstract available. PubMed 38419159 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.

Of 66 phase 3 interventional studies under Kidney Failure, Chronic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 48. This study's planned 31 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2022
First posted
Jul 5, 2023
StartActual
May 22, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added. Atlanta VA Medical and Rehab Center, Decatur, GA is now Not yet recruiting
Show 10 added (10 United States)
  • Rocky Mountain Regional VA Medical Center, Aurora, CO · Aurora, United States
  • VA Connecticut Healthcare System West Haven Campus, West Haven, CT · West Haven, United States
  • Jesse Brown VA Medical Center, Chicago, IL · Chicago, United States
  • Durham VA Medical Center, Durham, NC · Durham, United States
  • Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC · Salisbury, United States
  • Philadelphia MultiService Center, Philadelphia, PA · Philadelphia, United States
  • VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA · Pittsburgh, United States
  • VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX · Dallas, United States
  • VA Salt Lake City Health Care System, Salt Lake City, UT · Salt Lake City, United States
  • VA Puget Sound Health Care System Seattle Division, Seattle, WA · Seattle, United States
Oct 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Atlanta VA Medical and Rehab Center, Decatur, GA · Decatur, United StatesContact S•••@va.gov→s•••@va.gov
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    10 sites added. Atlanta VA Medical and Rehab Center, Decatur, GA is now Not yet recruiting
    Show 10 added (10 United States)
    • Rocky Mountain Regional VA Medical Center, Aurora, CO · Aurora, United States
    • VA Connecticut Healthcare System West Haven Campus, West Haven, CT · West Haven, United States
    • Jesse Brown VA Medical Center, Chicago, IL · Chicago, United States
    • Durham VA Medical Center, Durham, NC · Durham, United States
    • Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC · Salisbury, United States
    • Philadelphia MultiService Center, Philadelphia, PA · Philadelphia, United States
    • VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA · Pittsburgh, United States
    • VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX · Dallas, United States
    • VA Salt Lake City Health Care System, Salt Lake City, UT · Salt Lake City, United States
    • VA Puget Sound Health Care System Seattle Division, Seattle, WA · Seattle, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Atlanta VA Medical and Rehab Center, Decatur, GA · Decatur, United StatesContact S•••@va.gov→s•••@va.gov
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05931276
Responsible party
Sponsor
First posted
Jul 5, 2023
Start date
May 22, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Christopher M Donnelly
Contact
Christopher.Donnelly2@va.gov
Jade Fiotto
Contact
Jade.Fiotto@va.gov
(617) 232-9500
Areef Ishani, MD MS
study chair · Minneapolis VA Health Care System, Minneapolis, MN

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metoprolol · Carvedilol

Start the discussion